Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31486424 | 0.92 | RAD52 (0.34) | RAD52AADAT | |
| Trifluoroacetic Acid SCHEMBL31486572 | 0.84 | P2RX7 (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL31486277 | 0.83 | AADAT (0.31) | AADAT | |
| SCHEMBL31486433 | 0.82 | P2RX3 (0.35) | AADAT | |
| Trifluoroacetic Acid SCHEMBL31486387 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL31486279 | 0.82 | — | — | |
| SCHEMBL31486261 | 0.78 | MAPK14 (0.37) | RAD52 | |
| Hydrochloric Acid SCHEMBL31486342 | 0.76 | P2RX7 (0.34) | AADAT | |
| SCHEMBL31486404 | 0.75 | HDAC6 (0.36) | AADAT | |
| SCHEMBL31486295 | 0.73 | KMT2A (0.33) | AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | RAD52 1180/4885AADAT 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.